Announcement PDF FerriScan® (liver iron measurement) Shareholder Update ASX: RHT 09 June 2015 Disclaimer _________________________________________________________________________________________________ This presentation has been prepared by Resonance Health and may contain forward-looking statements that are based on the board and management’s current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described. Forward looking statements contained in this presentation may include statements about future financial and operating results, status of regulatory submissions, possible or assumed future growth opportunities and risks and uncertainties that could affect Resonance Health’s products and services. These statements are not guarantees of future performance, involve certain risks, uncertainties and assumptions that are difficult to predict, and are based upon assumptions as to future events that may not prove accurate. Therefore, actual outcomes and results may differ materially from what is expressed herein. In any forward looking statement in which Resonance Health expresses an expectation or belief as to future results, such expectation or belief is expressed in good faith and believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will result or be achieved or accomplished. You are urged to view all forward-looking statements contained herein with caution. Company Snapshot _________________________________________________________________________________________________ Financial Profile ASX Code: Share Price: Share Price History RHT FerriScan® 4.5cents (liver iron measurement) Market Capitalisation $18.07m Cash 31st March 2015 $2.9m No Debt Top 20 Shareholders – 45% Experienced Board and Management team, established relationships with pharmaceutical companies, expertise to commercialise development pipeline. Liver Fibrosis Market _________________________________________________________________________________________________ Market Information: • Large addressable market for a non-invasive liver fibrosis diagnosticFerriScan® (liver iron measurement) • Liver fibrosis (scarring) is caused by: • Fatty liver disease • • 1/3 of American adults have fatty liver prevalence of fatty liver disease in China has approx doubled in the past decade • Viral hepatitis (affecting 170m worldwide, 2.7m US, 200k+ UK) • Iron overload and excess alcohol consumption • Liver fibrosis can progress to liver cirrhosis and is a significant predictor of liver cancer Liver Fibrosis Market _________________________________________________________________________________________________ Clinical Need: • Early diagnosis of fibrosis and effective management can significantly • improve patient ®outcomes FerriScan (liver iron measurement) Pharmaceutical companies and clinicians need access to an accurate non-invasive diagnostic tool to assess liver fibrosis • Pharma companies working in this area include: - Intercept - Galmed - Gilead - Shire - Immuron - Conatus Company Product Overview _________________________________________________________________________________________________ Research Prototype Validate U.S. 510K FerriScan® (liver iron measurement) On Market Reimbursement (Canada/ UK) Cardiac T2* (cardiac iron assessment) HepaFat-Scan® (liver fat measurement) Liver Fibrosis Test R&D Prototype developed. Preparing for validation study. Technology used to non-invasively identify fibrosis may have wider potential applications. Identify conditions with unmet need for non-invasive biomarkers. FerriScan® & HepaFat-Scan® _________________________________________________________________________________________________ FerriScan: • Non-invasive Liver Iron Concentration (LIC) measurement • FDA, TGA and CE mark clearance ® (liver iron measurement) FerriScan • Accepted as gold standard LIC measurement • Profitable operation • Continued interest from pharmaceutical companies HepaFat-Scan: • Non-invasive liver fat measurement • FDA, TGA and CE mark clearance • Winner of WA Innovator of the Year • Collaboration with KOLs in the clinical community to participate in a • number of studies which will generate data to enhance the acceptance and uptake of HepaFat-Scan Agreement has been reached to commence the first study: 12 – 18 month US study in a paediatric patient cohort with NAFLD Contact _________________________________________________________________________________________________ • Adrian Bowers (CFO) AdrianB@resonancehealth.com • Sander Bangma (GM) SanderB@resonancehealth.com • P: +61 (0)8 9286 5300 E: info@resonancehealth.com W: www.resonancehealth.com